Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fifty-nine patients with severe chronic heart failure were given pirbuterol, a beta agonist with vasodilator and positive inotropic properties. The acute haemodynamic responses to both single (20 patients) and incremental doses (39 patients) were measured. Pirbuterol increased cardiac index and reduced left ventricular filling pressure and systemic vascular resistance with only small changes in heart rate and blood pressure. Maximal effects were observed at an average of 170 minutes after a single oral dose of pirbuterol. In the incremental dose studies the plasma pirbuterol concentration was found to increase with increasing doses and was related to the magnitude of the haemodynamic response. Pirbuterol was well tolerated, and no drug-related side effects were recorded. Oral pirbuterol clearly improved pump performance in these patients, the haemodynamic changes being consistent with vasodilatation as the dominant mechanism rather than a direct inotropic effect.
 ...
PMID:Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses. 611 39

Pirbuterol (PB), an oral beta-adrenergic-receptor agonist, has the pharmacologic effects of vasodilation and positive inotropy. The present studies were undertaken to determine the value of PB in the long-term therapy of chronic cardiac failure. A double-blind, randomized, 7-week trial comparing PB (20 mg three times daily) with placebo in 12 patients was followed by 12 weeks of open PB therapy. Dose-dependent nervousness and tremulousness limited the unit PB dose to less than 20 mg in six patients. In all patients, clinical status, exercise tolerance and maximal oxygen uptake, left ventricular echocardiographic dimension and cardiothoracic ratio were unchanged from control after 7 weeks of placebo or PB or after 12--19 weeks of PB. To assess the adequacy of 20 mg of PB, the dose-response relations of cardiocirculatory effects to 10, 15, 20 and 30 mg of PB were compared in seven of the above patients and nine other patients. Cardiac output was significantly elevated and wedge pressure reduced after all four doses, but these changes were sustained from 6 hours after 20- and 30-mg doses only. Thus, the role of PB in the management of chronic cardiac failure appears limited; judgment of its utility must await the results of additional controlled trials.
 ...
PMID:Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure. 612 86

The effects of the beta-adrenergic receptor agonist pirbuterol on left ventricular (LV) performance were examined during acute ischaemic LV failure in anaesthetized dogs. Plastic microspheres (50 microns) were injected into the left main coronary artery, and the dogs developed severe LV failure. The stability of the heart failure model was demonstrated in a group of untreated control dogs (n = 5). Administration of pirbuterol 7 micrograms X kg-1 i.v. during failure caused an increase in cardiac output from 1.52 +/- 0.14 (mean +/- S.E.M., n = 7) to 2.56 +/- 0.32 1 X min-1 (P less than 0.01) at 30 min after drug administration. The LV end-diastolic pressure (LVEDP) decreased from 24.6 +/- 1.1 to 21.0 +/- 1.9 mmHg (P less than 0.05), and maximum LV dP/dt was increased from 2012 +/- 124 to 2602 +/- 119 mmHg X s-1 (P less than 0.01). The LVEDP-stroke work relation (n = 2) shifted markedly upward. Heart rate was not significantly changed by pirbuterol. Mean aortic blood pressure and total peripheral resistance decreased from 103 +/- 3 to 85 +/- 5 mmHg (P less than 0.05) and from 68 +/- 6 to 34 +/- 4 mmHg X 1(-1) X min (P less than 0.01), respectively. Pirbuterol increased plasma free fatty acid concentrations from 264 +/- 45 (n = 4) to a maximum value of 956 +/- 169 mumol X 1(-1). In conclusion, by a combination of inotropic stimulation and systemic vasodilation, pirbuterol markedly improved cardiac performance in dogs with acute ischaemic LV failure.
 ...
PMID:Effects of the beta-adrenergic receptor agonist pirbuterol on cardiac performance during acute ischaemic left ventricular failure in dogs. 613 59